This guidance update reflects changes made to the required data elements for reporting as well as the cadence with which these elements need to be reported to CDC’s National Healthcare Safety Network (NHSN) following the expiration of the federal COVID-19 public health emergency declaration. There are no significant changes or additions to the reporting questions as a result of this guidance update. Information on reporting to NHSN can be found here: https://www.cdc.gov/nhsn/covid19/hospital-reporting.html.

This dataset tracks the updates made on the dataset "COVID Hospital Data Reporting Guidance Post-PHE" as a repository for previous versions of the data and metadata.

Global L Phenylalanine L Phe market size 2025 was XX Million. L Phenylalanine L Phe Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

State level COVID-19 metrics. As of 6/1/2023 this data set is no longer being updated. The COVID-19 Data Report is posted on the Open Data Portal every day at 3pm. The report uses data from multiple sources, including external partners; if data from external partners are not received by 3pm, they are not available for inclusion in the report and will not be displayed. Data that are received after 3pm will still be incorporated and published in the next report update. The cumulative number of COVID-19 cases (cumulative_cases) includes all cases of COVID-19 that have ever been reported to DPH. The cumulative number of COVID_19 cases in the last 7 days (cases_7days) only includes cases where the specimen collection date is within the past 7 days. While most cases are reported to DPH within 48 hours of specimen collection, there are a small number of cases that routinely are delayed, and will have specimen collection dates that fall outside of the rolling 7 day reporting window. Additionally, reporting entities may submit correction files to contribute historic data during initial onboarding or to address data quality issues; while this is rare, these correction files may cause a large amount of data from outside of the current reporting window to be uploaded in a single day; this would result in the change in cumulative_cases being much larger than the value of cases_7days. On June 4, 2020, the US Department of Health and Human Services issued guidance requiring the reporting of positive and negative test results for SARS-CoV-2; this guidance expired with the end of the federal PHE on 5/11/2023, and negative SARS-CoV-2 results were removed from the List of Reportable Laboratory Findings. DPH will no longer be reporting metrics that were dependent on the collection of negative test results, specifically total tests performed or percent positivity. Positive antigen and PCR/NAAT results will continue to be reportable.

Ac-Phe-Oet Market Outlook

The global Ac-Phe-Oet market size was estimated to be USD 245.3 million in 2023 and is projected to reach USD 428.5 million by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This growth can be attributed to the increased demand for Ac-Phe-Oet in various pharmaceutical and chemical synthesis applications, alongside advancements in research and development activities aimed at discovering novel therapeutic applications.

One of the primary growth factors driving the Ac-Phe-Oet market is the surge in pharmaceutical research activities. The pharmaceutical industry is continually seeking new compounds and intermediates for drug development, and Ac-Phe-Oet has emerged as a crucial component in this quest. Its role as a building block in peptide synthesis makes it indispensable for designing new therapeutic agents, thereby fueling its market growth. Additionally, the increasing incidence of chronic diseases globally is pushing pharmaceutical companies to invest heavily in R&D, further amplifying the demand for Ac-Phe-Oet.

Another significant growth factor is the expanding research and development sector. Research institutions and universities across the globe are focusing on exploring the potential applications of Ac-Phe-Oet. Foundational research into the biochemistry of peptides and their analogs is crucial for developing innovative treatments for a range of diseases. Government grants and funding from private organizations aimed at promoting scientific discoveries are also contributing to the increasing demand for this compound.

The chemical synthesis industry also plays a vital role in driving the market for Ac-Phe-Oet. This compound is extensively used as an intermediate in the synthesis of various chemical products. The growing chemical industry, especially in developing countries, is contributing to the increased demand for high-purity Ac-Phe-Oet for the manufacturing of specialty chemicals and materials. The compound’s versatility and effectiveness in chemical synthesis make it a valuable asset in this industry.

From a regional perspective, the Asia Pacific region is expected to witness the highest growth in the Ac-Phe-Oet market. This can be attributed to the region’s booming pharmaceutical and chemical industries, supported by favorable government policies and increasing foreign investments. North America and Europe are also significant markets due to their advanced research infrastructure and the presence of leading pharmaceutical companies. However, markets in regions like Latin America and the Middle East & Africa are anticipated to grow at a steady pace, driven by gradual industrialization and expanding research activities.

Product Type Analysis

The Ac-Phe-Oet market is segmented by product type into two categories: Purity ≥ 98% and Purity < 98%. The Purity ≥ 98% segment is expected to dominate the market during the forecast period. This can be attributed to the high demand for superior quality compounds in pharmaceutical and research applications. High-purity Ac-Phe-Oet ensures better efficacy and safety in drug development processes, which is a crucial requirement for pharmaceutical companies. Consequently, this segment is anticipated to witness significant growth, driven by the stringent quality standards in the pharmaceutical sector.

The Purity < 98% segment, while smaller in comparison, also holds a substantial share of the market. This product type is typically used in applications where ultra-high purity is not a critical requirement, such as certain chemical synthesis processes. The cost-effectiveness of lower purity Ac-Phe-Oet makes it an attractive choice for chemical companies looking to optimize production costs without compromising the quality of their end products. As the chemical manufacturing sector continues to expand, this segment is expected to maintain a steady growth trajectory.

Demand for high-purity Ac-Phe-Oet is particularly strong in developed regions such as North America and Europe, where stringent regulatory standards necessitate the use of high-quality intermediates in pharmaceutical manufacturing. In contrast, the Purity < 98% segment finds more significant uptake in developing regions where cost considerations play a more pivotal role in procurement decisions. The market dynamics between these two product type segments highlight the diverse requirements and strategic decisions of end-users across different regions.

The increasing focus on precision medic

Town Level COVID-19 Data As of 6/1/2023, this data set is no longer being updated. The COVID-19 Data Report is posted on the Open Data Portal every day at 3pm. The report uses data from multiple sources, including external partners; if data from external partners are not received by 3pm, they are not available for inclusion in the report and will not be displayed. Data that are received after 3pm will still be incorporated and published in the next report update. Suppression: the data in towns with fewer than five (5) cases or five (5) positive NAAT tests in the past seven (7) days are suppressed. The cumulative number of COVID-19 cases (cumulative_cases) includes all cases of COVID-19 that have ever been reported to DPH. The cumulative number of COVID_19 cases in the last 7 days (cases_7days) only includes cases where the specimen collection date is within the past 7 days. While most cases are reported to DPH within 48 hours of specimen collection, there are a small number of cases that routinely are delayed, and will have specimen collection dates that fall outside of the rolling 7 day reporting window. Additionally, reporting entities may submit correction files to contribute historic data during initial onboarding or to address data quality issues; while this is rare, these correction files may cause a large amount of data from outside of the current reporting window to be uploaded in a single day; this would result in the change in cumulative_cases being much larger than the value of cases_7days. On June 4, 2020, the US Department of Health and Human Services issued guidance requiring the reporting of positive and negative test results for SARS-CoV-2; this guidance expired with the end of the federal PHE on 5/11/2023, and negative SARS-CoV-2 results were removed from the List of Reportable Laboratory Findings. DPH will no longer be reporting metrics that were dependent on the collection of negative test results, specifically total tests performed or percent positivity. Positive antigen and PCR/NAAT results will continue to be reportable.

Covid-19 Daily metrics at the county level

As of 6/1/2023, this data set is no longer being updated.

The COVID-19 Data Report is posted on the Open Data Portal every day at 3pm. The report uses data from multiple sources, including external partners; if data from external partners are not received by 3pm, they are not available for inclusion in the report and will not be displayed. Data that are received after 3pm will still be incorporated and published in the next report update.

The cumulative number of COVID-19 cases (cumulative_cases) includes all cases of COVID-19 that have ever been reported to DPH. The cumulative number of COVID_19 cases in the last 7 days (cases_7days) only includes cases where the specimen collection date is within the past 7 days. While most cases are reported to DPH within 48 hours of specimen collection, there are a small number of cases that routinely are delayed, and will have specimen collection dates that fall outside of the rolling 7 day reporting window. Additionally, reporting entities may submit correction files to contribute historic data during initial onboarding or to address data quality issues; while this is rare, these correction files may cause a large amount of data from outside of the current reporting window to be uploaded in a single day; this would result in the change in cumulative_cases being much larger than the value of cases_7days.

On June 4, 2020, the US Department of Health and Human Services issued guidance requiring the reporting of positive and negative test results for SARS-CoV-2; this guidance expired with the end of the federal PHE on 5/11/2023, and negative SARS-CoV-2 results were removed from the List of Reportable Laboratory Findings. DPH will no longer be reporting metrics that were dependent on the collection of negative test results, specifically total tests performed or percent positivity. Positive antigen and PCR/NAAT results will continue to be reportable.

KPI's for the performance Total rural population with access to safe drinking water Total number of samples collected for water quality test in the District during the reporting month Total Number of new sanitation schemes completed till date in CFY Total Number of new water supply schemes completed till date CFY Total number of existing functional PHE tube-wells Total amount of revenue collected till date in current financial year Total number of water pipeline repaired in the District during the reporting month

The Z-P-Fluoro-Phe-OH reagent market is experiencing robust growth, driven by increasing demand in pharmaceutical and biotechnology research. This specialized reagent plays a crucial role in peptide synthesis, particularly in the development of novel drugs and therapeutic peptides. While precise market figures are not provided, a reasonable estimation, considering typical growth rates in the specialty chemical sector and the expanding applications of peptide-based therapies, places the 2025 market size at approximately $150 million. Assuming a Compound Annual Growth Rate (CAGR) of 8% – a conservative estimate given market dynamism and technological advancements – the market is projected to reach approximately $250 million by 2033. Key drivers include the rising prevalence of chronic diseases necessitating advanced drug development, the growing adoption of peptide therapeutics, and continuous innovation in peptide synthesis technologies. Market trends indicate a shift toward higher-purity reagents and increased demand for custom synthesis services to cater to specialized research needs. However, potential restraints include the high cost of the reagent and the stringent regulatory requirements associated with pharmaceutical applications. The competitive landscape is relatively fragmented, with key players like Watanabe Chemical Industries, ChemPep, Toronto Research Chemicals, Alchem Pharmtech, chemcube, Beta Pharma Scientific, and AMRI vying for market share. These companies are focusing on enhancing product quality, expanding their product portfolio, and forging strategic partnerships to strengthen their market position. Future growth will depend on successful collaborations between reagent manufacturers and pharmaceutical companies, along with continued investment in research and development to improve synthesis efficiency and reduce costs. Regional variations exist, with North America and Europe likely holding the largest market shares due to their established pharmaceutical industries and robust research infrastructure. However, growth in emerging markets such as Asia-Pacific is anticipated to gain momentum in the coming years driven by increasing investments in life sciences and healthcare.

During a public health emergency in the Families First Coronavirus Response Act (FFCRA), a new optional Medicaid eligibility group was added called COVID-19 testing eligibility group. States reported these expenditures under sections 6004 and 6008 through the Medicaid Budget and Expenditure System (MBES) on the Form CMS-64. The data in these reports constitute summary level preliminary expenditure information related to these FFCRA provisions for each state Notes: 1. The Families First Coronavirus Response Act (FFCRA), enacted on March 18, 2020, provided a temporary FMAP increase to states and territories meeting certain qualifications and added a new optional Medicaid eligibility group for uninsured individuals during a public health emergency in section 1902(a)(10)(A)(ii)(XXIII) of the Act, referred to as the “COVID - 19 Testing Group.” 2. FFCRA Section 6008 provides a temporary 6.2 percentage point FMAP increase to each qualifying state and territory's FMAP under section 1905(b) of the Act, beginning January 1, 2020 and lasting through the end of the quarter in which the public health emergency (PHE) declared by the Secretary for COVID-19 ends, including any extensions. 3. FFCRA Section 6004 provides a 100 percent match rate for individuals eligible under the new optional Medicaid eligibility group in section 1902(a)(10)(A)(ii)(XXIII) of the Act, beginning no earlier than March 18, 2020 and lasting through the end of the PHE for COVID-19. 4. States that have reported “0” either have no expenditures for that reporting category or have not yet reported expenditures for that category. 5. This report is a cumulative summary report that includes current and prior period adjustment expenditures that apply to this quarter 6. For the Quarter ending 03/31/2020: Delaware has Negative Total Computable Expenditures and Total Federal Share Expenditures due to the reporting of prior period adjustments during this period. 7. For the Quarter ending 09/30/2020: Colorado has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 8. For the Quarter ending 03/31/2021: California has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. This corrected FY 2020 Q4 expenditures for Treatment services that are not allowed for Section 6004 100% FMAP match. 9. For the Quarter ending 03/31/2021: Utah has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 10. For the Quarter ending 12/31/2022: California has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 11. For the Quarter ending 12/31/2022: Connecticut has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 12. For the Quarter ending 09/30/2023: Connecticut has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 13. For the Quarter ending 09/30/2023: Illinois has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid 19 Expenditures due to the reporting of prior period adjustments during this period. 14. For the Quarter ending 09/30/2023: Minnesota has Negative Total Computable Section 6004 Covid 19 Expenditures and Total Federal Share Section 6004 Covid

Explore Market Research Intellect's Plug-in Hybrid Drivetrain (PHE) Market Report, valued at USD 22 billion in 2024, with a projected market growth to USD 45 billion by 2033, and a CAGR of 8.5% from 2026 to 2033.

L Phenylalanine (L Phe) Market Outlook

The global L Phenylalanine (L Phe) market size was valued at approximately USD 1.8 billion in 2023 and is projected to reach around USD 2.9 billion by 2032, growing at a compounded annual growth rate (CAGR) of 5.5% during the forecast period. This notable growth is primarily driven by increasing demand from the pharmaceutical and nutraceutical industries, alongside a rising awareness about health and wellness among consumers globally.

One of the primary growth factors fueling the L Phenylalanine market is its critical role in the production of various pharmaceuticals. As a precursor to several bioactive compounds, including dopamine, adrenaline, and noradrenaline, L Phenylalanine is essential in treating conditions such as depression and chronic pain. The pharmaceutical industry's expansion, driven by an aging population and rising prevalence of chronic diseases, significantly boosts the demand for high-quality pharmaceutical-grade L Phenylalanine.

In the food and beverage sector, L Phenylalanine's application as a crucial component in artificial sweeteners, like aspartame, is a significant growth driver. With increasing consumer inclination towards sugar-free and low-calorie products, the demand for such sweeteners is experiencing an upward trend. As a result, food-grade L Phenylalanine consumption is expected to rise, especially in developed regions where the awareness about healthy eating practices is more pronounced.

The nutritional supplements industry also significantly contributes to the market's growth. As a dietary supplement, L Phenylalanine is valued for its potential benefits in enhancing mental alertness, improving mood, and aiding in weight loss. The growing popularity of fitness and wellness trends among consumers, coupled with the rise of e-commerce platforms facilitating easy access to supplements, supports the expanding demand for L Phenylalanine in this segment.

L-Leucine is another essential amino acid that plays a critical role in various metabolic functions. It is particularly renowned for its ability to stimulate muscle protein synthesis, making it a popular supplement among athletes and bodybuilders. The increasing awareness of fitness and muscle health has driven the demand for L-Leucine in the nutritional supplements market. As consumers become more health-conscious, the integration of L-Leucine in dietary regimens is seen as beneficial for muscle recovery and growth. This trend is expected to continue, contributing to the broader amino acid market's expansion.

Regionally, North America and Europe dominate the L Phenylalanine market owing to advanced healthcare infrastructure, high disposable income, and a strong presence of pharmaceutical companies. However, the Asia Pacific region is anticipated to exhibit the highest growth rate during the forecast period. This growth is attributed to the rapidly developing pharmaceutical and food processing industries, along with increasing health awareness among consumers in emerging economies like China and India.

Product Type Analysis

The L Phenylalanine market can be segmented based on product type into pharmaceutical grade, food grade, and feed grade. Pharmaceutical-grade L Phenylalanine holds the largest market share due to its extensive use in the medical field. This grade is characterized by its high purity and stringent manufacturing standards, making it suitable for critical applications in drug formulations. The growing pharmaceutical industry, especially in developed regions, underscores the demand for high-quality L Phenylalanine to meet regulatory standards and therapeutic efficacy.

L-aspartic acid, another vital amino acid, is gaining attention for its role in energy production and neurotransmitter synthesis. It is a key component in the urea cycle, helping to detoxify ammonia in the liver. As the demand for functional foods and supplements rises, L-aspartic acid is increasingly being incorporated into products aimed at enhancing energy levels and cognitive function. This amino acid's ability to support metabolic processes and improve athletic performance makes it a valuable addition to the health and wellness sector, further driving its market growth.

Food-grade L Phenylalanine is another significant segment, driven by i